Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Therapeutics reported a net loss of $30.2M for the quarter and $60.0M for the six months ended April 30, 2026, driven by research and development and growing general and administrative costs. Operating cash outflow was $59.4M over six months.
The company held $29.8M in cash and cash equivalents and $255.2M in marketable securities, with total assets of $307.5M and shareholders’ equity of $255.2M. Management expects this liquidity to fund operations and debt obligations for at least 12 months, but anticipates needing additional capital thereafter.
enGene expanded its debt facility to up to $125M, drawing $25M, and raised equity through a late-2025 public offering and pre-funded warrants. Subsequent to quarter-end, it announced a workforce reduction of about 50% and a strategic restructuring to preserve cash while advancing its LEGEND trial of detalimogene and preparing for a potential BLA filing.
enGene Therapeutics reported a net loss of $30.2M for the quarter and $60.0M for the six months ended April 30, 2026, driven by research and development and growing general and administrative costs. Operating cash outflow was $59.4M over six months.
The company held $29.8M in cash and cash equivalents and $255.2M in marketable securities, with total assets of $307.5M and shareholders’ equity of $255.2M. Management expects this liquidity to fund operations and debt obligations for at least 12 months, but anticipates needing additional capital thereafter.
enGene expanded its debt facility to up to $125M, drawing $25M, and raised equity through a late-2025 public offering and pre-funded warrants. Subsequent to quarter-end, it announced a workforce reduction of about 50% and a strategic restructuring to preserve cash while advancing its LEGEND trial of detalimogene and preparing for a potential BLA filing.
enGene Therapeutics reported a Q2 2026 net loss of $30.2 million, or $0.43 per share, as total operating expenses rose to $32.0 million from $27.1 million a year earlier, driven by higher research, clinical and administrative costs.
Cash, cash equivalents and marketable securities were $285.2 million as of April 30, 2026, supporting ongoing development of detalimogene. Interim data from the LEGEND pivotal Cohort 1 showed a 54% complete response rate (67/124 patients) with a 3.2% progression rate in high-risk BCG‑unresponsive NMIBC.
The company is implementing a strategic restructuring, including an approximately 50% workforce reduction, with estimated restructuring costs of $5.7–$6.4 million plus $4.7–$5.0 million in non‑cash stock‑based compensation. Several senior executives, including the CFO, CMO, CLO and CSO, are departing, while new finance leadership and an interim CMO have been appointed.
enGene Therapeutics reported a Q2 2026 net loss of $30.2 million, or $0.43 per share, as total operating expenses rose to $32.0 million from $27.1 million a year earlier, driven by higher research, clinical and administrative costs.
Cash, cash equivalents and marketable securities were $285.2 million as of April 30, 2026, supporting ongoing development of detalimogene. Interim data from the LEGEND pivotal Cohort 1 showed a 54% complete response rate (67/124 patients) with a 3.2% progression rate in high-risk BCG‑unresponsive NMIBC.
The company is implementing a strategic restructuring, including an approximately 50% workforce reduction, with estimated restructuring costs of $5.7–$6.4 million plus $4.7–$5.0 million in non‑cash stock‑based compensation. Several senior executives, including the CFO, CMO, CLO and CSO, are departing, while new finance leadership and an interim CMO have been appointed.
enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders. The meeting was held on June 9, 2026, with 56,196,302 common shares represented, about 83.89% of the 66,989,466 shares outstanding and entitled to vote as of April 28, 2026.
Shareholders voted on the election of directors and on the appointment and remuneration of the auditor. Director nominees, including Philip Astley-Sparke and Ronald H.W. Cooper, each received more than 47.1 million votes “for,” with relatively few “withhold” votes and substantial broker non-votes. The auditor proposal received 56,180,287 votes “for” and 16,015 “withhold.”
enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders. The meeting was held on June 9, 2026, with 56,196,302 common shares represented, about 83.89% of the 66,989,466 shares outstanding and entitled to vote as of April 28, 2026.
Shareholders voted on the election of directors and on the appointment and remuneration of the auditor. Director nominees, including Philip Astley-Sparke and Ronald H.W. Cooper, each received more than 47.1 million votes “for,” with relatively few “withhold” votes and substantial broker non-votes. The auditor proposal received 56,180,287 votes “for” and 16,015 “withhold.”
enGene Holdings Inc. filed an Amendment No. 1 Schedule 13G/A reporting that Cormorant Asset Management, LP and Bihua Chen hold 0 shares of Common Stock, representing 0% of the class. The filing cites 66,989,466 shares outstanding as of March 3, 2026.
The statement clarifies the reporting persons act as investment adviser to certain funds and that the filing should not be construed as an admission of beneficial ownership under Section 13. The signature date shown is May 15, 2026.
enGene Holdings Inc. filed an Amendment No. 1 Schedule 13G/A reporting that Cormorant Asset Management, LP and Bihua Chen hold 0 shares of Common Stock, representing 0% of the class. The filing cites 66,989,466 shares outstanding as of March 3, 2026.
The statement clarifies the reporting persons act as investment adviser to certain funds and that the filing should not be construed as an admission of beneficial ownership under Section 13. The signature date shown is May 15, 2026.
BML Investment Partners, L.P. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 6,669,908 common shares of enGene Holdings Inc. The filing states these shares represent 9.95% of the class as of the report and lists shared voting and shared dispositive power over those shares. The filing identifies the reporting person as BML Investment Partners, L.P. (a Delaware limited partnership) and discloses that BML Capital Management, LLC and Braden M. Leonard are indirect owners/agents with signature dated 05/14/2026.
BML Investment Partners, L.P. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 6,669,908 common shares of enGene Holdings Inc. The filing states these shares represent 9.95% of the class as of the report and lists shared voting and shared dispositive power over those shares. The filing identifies the reporting person as BML Investment Partners, L.P. (a Delaware limited partnership) and discloses that BML Capital Management, LLC and Braden M. Leonard are indirect owners/agents with signature dated 05/14/2026.
enGene Holdings Inc. ownership disclosure: BML Investment Partners, L.P. reports beneficial ownership of 5,225,000 common shares, representing 7.8% of the class as shown on 05/08/2026. The filing states shared voting and dispositive power over these shares through BML Capital Management, LLC and Braden M. Leonard.
enGene Holdings Inc. ownership disclosure: BML Investment Partners, L.P. reports beneficial ownership of 5,225,000 common shares, representing 7.8% of the class as shown on 05/08/2026. The filing states shared voting and dispositive power over these shares through BML Capital Management, LLC and Braden M. Leonard.
enGene Therapeutics Inc. is asking shareholders to vote at a virtual-only annual general meeting on June 9, 2026. Holders of common shares at the April 28, 2026 record date can participate online, vote, and submit questions via live audio webcast.
Shareholders will vote on electing four directors to three-year terms and on appointing KPMG as auditors, with the board recommending “FOR” on both items. Quorum requires at least two persons representing at least 33⅓% of shares entitled to vote.
enGene Therapeutics Inc. is asking shareholders to vote at a virtual-only annual general meeting on June 9, 2026. Holders of common shares at the April 28, 2026 record date can participate online, vote, and submit questions via live audio webcast.
Shareholders will vote on electing four directors to three-year terms and on appointing KPMG as auditors, with the board recommending “FOR” on both items. Quorum requires at least two persons representing at least 33⅓% of shares entitled to vote.
enGene Therapeutics Inc. reported updated interim results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC, and amended the employment agreement of Dr. Hussein Sweiti. Among 125 patients, detalimogene achieved a 54% complete response rate at any time and 43% at six months, with a low 3.2% progression rate to muscle-invasive or more advanced disease. Treatment-related adverse events occurred in 55% of patients, were mainly Grade 1–2, and led to dose interruptions or discontinuations in 2.4% of patients each. A Kaplan-Meier estimate showed a 12‑month complete response rate of 25%, and later-enrolling patients had lower response rates than earlier subgroups, which the company is further analyzing.
enGene Therapeutics Inc. reported updated interim results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC, and amended the employment agreement of Dr. Hussein Sweiti. Among 125 patients, detalimogene achieved a 54% complete response rate at any time and 43% at six months, with a low 3.2% progression rate to muscle-invasive or more advanced disease. Treatment-related adverse events occurred in 55% of patients, were mainly Grade 1–2, and led to dose interruptions or discontinuations in 2.4% of patients each. A Kaplan-Meier estimate showed a 12‑month complete response rate of 25%, and later-enrolling patients had lower response rates than earlier subgroups, which the company is further analyzing.
enGene Therapeutics Inc. holders led by Invus-related entities and Avicenna reported beneficial ownership positions in an amended Schedule 13G/A. As of March 31, 2026, Invus Public Equities directly held 4,513,228 shares and Avicenna Life Sci Master Fund directly held 739,931 shares. The filing states percentages based on 66,989,466 Shares outstanding as of March 3, 2026, with Invus Public Equities and related reporting persons shown at 6.7% and Mr. Raymond Debbane shown at 7.8%.
The cover and Item 4 describe control relationships among Invus Public Equities, Invus PE Advisors, Invus Global Management, Siren, Avicenna GP, Ulys and Mr. Debbane; each reporting person certifies the holdings were not acquired to change control. Signatures are dated May 5, 2026.
enGene Therapeutics Inc. holders led by Invus-related entities and Avicenna reported beneficial ownership positions in an amended Schedule 13G/A. As of March 31, 2026, Invus Public Equities directly held 4,513,228 shares and Avicenna Life Sci Master Fund directly held 739,931 shares. The filing states percentages based on 66,989,466 Shares outstanding as of March 3, 2026, with Invus Public Equities and related reporting persons shown at 6.7% and Mr. Raymond Debbane shown at 7.8%.
The cover and Item 4 describe control relationships among Invus Public Equities, Invus PE Advisors, Invus Global Management, Siren, Avicenna GP, Ulys and Mr. Debbane; each reporting person certifies the holdings were not acquired to change control. Signatures are dated May 5, 2026.
enGene Therapeutics Inc., formerly enGene Holdings Inc., has changed its corporate name to enGene Therapeutics Inc., effective April 8, 2026. The amendment affects only the name; no other changes were made to the company’s articles. The company’s common shares and warrants will continue trading on Nasdaq under the symbols ENGN and ENGNW, respectively.
In a related press release, enGene explained that the new name reflects its transition toward potential commercialization of its lead gene therapy detalimogene voraplasmid. The company plans a Biologics License Application submission for detalimogene in the second half of 2026, targeting potential approval and a commercial organization in 2027.
enGene Therapeutics Inc., formerly enGene Holdings Inc., has changed its corporate name to enGene Therapeutics Inc., effective April 8, 2026. The amendment affects only the name; no other changes were made to the company’s articles. The company’s common shares and warrants will continue trading on Nasdaq under the symbols ENGN and ENGNW, respectively.
In a related press release, enGene explained that the new name reflects its transition toward potential commercialization of its lead gene therapy detalimogene voraplasmid. The company plans a Biologics License Application submission for detalimogene in the second half of 2026, targeting potential approval and a commercial organization in 2027.